A Phase 4 interventional study of Denosumab treatment in osteoporotic patients and Teriparatide treatment in osteoporotic patients in Osteoporosis, sponsored by Shinshu University. Status unknown at 1 site in Japan. Open to participants aged 1 Year to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-22.
Sponsored by Shinshu University · Phase 4, Interventional, and Treatment
It has not been well known about the changes of bone metabolic markers, bone mineral density and other bone-related markers after teriparatide and/or denosumab treatment in Japanese osteoporotic patients.
1,640 studies on the registry are indexed under Osteoporosis; 212 are open to participants now.
This study's planned enrollment of 100 is close to the median of 95 across 1,133 interventional studies indexed under Osteoporosis.
Browse Osteoporosis studies →Shinshu University is the lead sponsor of 16 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Denosumab and/or teriparatide treatment in osteoporotic patients
Drug: Denosumab treatment in osteoporotic patients · Drug: Teriparatide treatment in osteoporotic patients · Drug: Denosumab and teriparatide treatment in osteoporotic patients
To examine the effectiveness of denosumab in osteoporotic patients
To examine the effectiveness of teriparatide in osteoporotic patients
To examine the effectiveness of denosumab and teriparatide in osteoporotic patients
Changes of bone mineral density
Bone mineral density will be examined every 4-6 months to evaluate the suitability of the drug.
Time frame: every 4-6 months
Changes of bone turnover markers
Bone turnover markers will be examined every 3-6 months to evaluate the suitability of the drug.
Time frame: every 3-6 months
This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shinshu University